Figure S4

1
Figure S4 JURKAT + imatinib JURL-MK1 + dasatinib -11 -10 -9 -8 -7 -6 -5 -4 0 50 100 log[dasatinib](M ) M FI (% ofcontrol) JURL-MK1 + imatinib -8 -7 -6 -5 -4 0 50 100 log[im atinib](M ) M FI (% ofcontrol) MOLM-7 + dasatinib -11 -10 -9 -8 -7 -6 -5 -4 0 50 100 log[dasatinib](M ) M FI (% ofcontrol) MOLM-7 + imatinib -8 -7 -6 -5 -4 0 50 100 log[im atinib](M ) M FI (% ofcontrol) HEL + imatinib -8 -7 -6 -5 -4 0 50 100 log[im atinib](M ) M FI (% ofcontrol) -8 -7 -6 -5 -4 0 50 100 150 log[im atinib](M ) M FI (% ofcontrol)

description

JURL-MK1 + dasatinib. JURL-MK1 + imatinib. MOLM-7 + dasatinib. MOLM-7 + imatinib. JURKAT + imatinib. HEL + imatinib. Figure S4. - PowerPoint PPT Presentation

Transcript of Figure S4

Page 1: Figure  S4

Figure S4

JURKAT + imatinib

JURL-MK1 + dasatinib

-11 -10 -9 -8 -7 -6 -5 -40

50

100

log[dasatinib] (M)

MFI

(% o

f co

ntr

ol)

JURL-MK1 + imatinib

-8 -7 -6 -5 -40

50

100

log[imatinib] (M)

MFI

(% o

f co

ntr

ol)

MOLM-7 + dasatinib

-11 -10 -9 -8 -7 -6 -5 -40

50

100

log[dasatinib] (M)

MFI

(% o

f co

ntr

ol)

MOLM-7 + imatinib

-8 -7 -6 -5 -40

50

100

log[imatinib] (M)

MFI

(% o

f co

ntr

ol)

HEL + imatinib

-8 -7 -6 -5 -40

50

100

log[imatinib] (M)

MFI

(% o

f co

ntr

ol)

-8 -7 -6 -5 -40

50

100

150

log[imatinib] (M)

MFI

(% o

f co

ntr

ol)